Scott_Halperin

Scott Halperin

Scott Halperin

Canadian immunologist, professor of pediatrics, microbiology, and immunology


Scott Halperin is a Canadian immunologist, professor of pediatrics, microbiology, and immunology at Dalhousie University, the head of Pediatric Infection Diseases at IWK Health Centre, and the director of the Canadian Centre for Vaccinology.[1][2][3]

Biography

Halperin received a B.Sc. from Stanford University, and an M.D. from Cornell University. He did his postdoctoral research in pediatric infectious diseases at the University of Virginia and University of Minnesota.[4]

Career

Halperin's research focuses on pertussis and other vaccine-preventable diseases.[2] In 2020, the Canadian Centre for Vaccinology at Dalhousie University was approved by Health Canada to begin clinical trial for a potential COVID-19 vaccine, led by Halperin.[5] Halperin's research also focuses on public health policy in relation to the COVID-19 pandemic.[6]

Awards

From 2004 to 2009, Halperin held the CIHR/Wyeth Pharmaceuticals clinical research chair in vaccines. He received a certificate of merit from the Canadian Paediatric Society in 2009, as well as the Max Forman Senior Research Prize from the Dalhousie Medical Research Foundation, also in 2009.[4]


References

  1. "COVID‑19 researcher profile: Dr. Scott Halperin". Dalhousie News. Retrieved 17 May 2020.
  2. "» Dr. Scott Halperin". 8 April 2013. Retrieved 17 May 2020.
  3. "Health Canada approves first clinical trial for potential COVID-19 vaccine". rdnewsnow.com. The Canadian Press. Retrieved 17 May 2020.
  4. "Scott Halperin". Dalhousie University. Retrieved 17 May 2020.
  5. Keith Doucette (17 May 2020). "Halifax lab to do COVID-19 vaccine trials". Winnipeg Free Press. The Canadian Press. Retrieved 17 May 2020.
  6. Cooke, Alex (9 March 2020). "Dalhousie researchers get $1.9M to study coronavirus". CBC. Retrieved 17 May 2020.

Share this article:

This article uses material from the Wikipedia article Scott_Halperin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.